Seres therapeutics to host second quarter 2017 financial results and operational progress conference call and webcast on august 3, 2017

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq:mcrb) today announced that management will host a conference call and live audio webcast on august 3, 2017 at 8:00 a.m. et to discuss second quarter 2017 results and provide a general business update. to access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference id number 62118608. to join the live webcast, please visit the “investors and media” section of the seres website at www.serestherapeutics.com. a webcast replay will be available on the seres website beginning approximately two hours after the event and will be archived for approximately 21 days. about seres therapeuticsseres therapeutics, inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. seres’ lead program, ser-109, has obtained breakthrough and orphan drug designations from the us food and drug administration and is in phase 3 development for multiply recurrent c. difficile infection. seres’ clinical candidate ser-287 is being evaluated in a phase 1b study in patients with mild-to-moderate ulcerative colitis. seres is also developing ser-262, the first ever synthetic microbiome therapeutic candidate, in a phase 1b study in patients with primary c. difficile infection. for more information, please visit www.serestherapeutics.com. follow us on twitter @serestx.
MCRB Ratings Summary
MCRB Quant Ranking